Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 22 Nov 22 424B3 Prospectus supplement
- 30 Aug 22 EFFECT Notice of effectiveness
-
24 Aug 22 POS AM Prospectus update (post-effective amendment)
- 19 Jul 22 424B5 Prospectus supplement for primary offering
- 5 Apr 22 EFFECT Notice of effectiveness
- 31 Mar 22 POS AM Prospectus update (post-effective amendment)
- 19 Jan 22 EFFECT Notice of effectiveness
- 19 Jan 22 424B3 Prospectus supplement
- 7 Jan 22 F-1 Registration statement (foreign)
ADXN similar filings
- 18 Apr 24 Prospectus update (post-effective amendment)
- 29 Nov 23 Prospectus update (post-effective amendment)
- 10 Aug 23 Prospectus update (post-effective amendment)
- 24 Aug 22 Prospectus update (post-effective amendment)
- 31 Mar 22 Prospectus update (post-effective amendment)
- 29 Mar 22 Prospectus update (post-effective amendment)
- 24 Apr 20 Prospectus update (post-effective amendment)
Filing view
External links
Exhibit 23.3
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Post-Effective Amendment No. 2 to the Registration Statement on Form F-1 (File No. 333-262050) of Addex Therapeutics Ltd of our report dated April 24, 2020 relating to the financial statements, which appears in Addex Therapeutics Ltd's Annual Report on Form 20-F for the year ended December 31, 2021. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ PricewaterhouseCoopers SA
Geneva, Switzerland
August 23, 2022
1